Search

Your search keyword '"Soza, Alejandro"' showing total 9 results
Start Over Author "Soza, Alejandro" Publisher elsevier b.v.
9 results on '"Soza, Alejandro"'

1. R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation

Author

Boudjema, Karim, Bachellier, Philippe, Conti, Filomena, Scatton, Olivier, Muscari, Fabrice, Salame, Ephrem, Bernard, Pierre Henri, Francoz, Claire, Durand, Francois, Dharancy, Sébastien, Woehl, Marie-lorraine, Vanlemmens, Claire, Laurent, Alexis, Radenne, Sylvie, Dumortier, Jérôme, Abergel, Armand, Cherqui, Daniel, Barbier, Louise, Houssel-Debry, Pauline, Pageaux, Georges Philippe, Chiche, Laurence, Deledinghen, Victor, Hardwigsen, Jean, Gugenheim, J., Altieri, M., Hilleret, Marie Noelle, Decaens, Thomas, Duvoux, Christophe, Piñero, Federico, Chagas, Aline, Costa, Paulo, Cristina de Ataide, Elaine, Quiñones, Emilio, Duque, Sergio Hoyos, Marciano, Sebastián, Anders, Margarita, Varón, Adriana, Zerega, Alina, Poniachik, Jaime, Soza, Alejandro, Machaca, Martín Padilla, Arufe, Diego, Menéndez, Josemaría, Zapata, Rodrigo, Vilatoba, Mario, Muñoz, Linda, Menéndez, Ricardo Chong, Maraschio, Martín, Podestá, Luis G., McCormack, Lucas, Mattera, Juan, Gadano, Adrian, Fatima Boin, Ilka S.F., Parente García, Jose Huygens, Carrilho, Flair, Silva, Marcelo, Notarpaolo, Andrea, Magini, Giulia, Miglioresi, Lucia, Gambato, Martina, Di Benedetto, Fabrizio, D’Ambrosio, Cecilia, Ettorre, Giuseppe Maria, Vitale, Alessandro, Burra, Patrizia, Fagiuoli, Stefano, Cillo, Umberto, Colledan, Michele, Pinelli, Domenico, Magistri, Paolo, Vennarecci, Giovanni, Colasanti, Marco, Giannelli, Valerio, Pellicelli, Adriano, Baccaro, Cizia, Lai, Quirino, Degroote, Helena, Van Vlierberghe, Hans, Eduard, Callebout, Samuele, Iesari, Jeroen, Dekervel, Jonas, Schreiber, Jacques, Pirenne, Chris, Verslype, Dirk, Ysebaert, Peter, Michielsen, Valerio, Lucidi, Christophe, Moreno, Olivier, Detry, Jean, Delwaide, Roberto, Troisi, Paul, Lerut Jan, Costentin, Charlotte, Boin, Ilka F., Baccaro, Cinzia, Dibenedetto, Fabrizio, Marciano, Sebastian, and Rubinstein, Fernando

Published
2022
Full Text
View/download PDF

2. International study on the outcome of locoregional therapy for liver transplant in hepatocellular carcinoma beyond Milan criteria

Author

Boudjema, Karim, Bachellier, Philippe, Conti, Filomena, Scatton, Olivier, Muscari, Fabrice, Salame, Ephrem, Bernard, Pierre Henri, Francoz, Claire, Durand, Francois, Dharancy, Sébastien, Woehl, Marie-lorraine, Vanlemmens, Claire, Laurent, Alexis, Radenne, Sylvie, Dumortier, Jérôme, Abergel, Armand, Cherqui, Daniel, Barbier, Louise, Houssel-Debry, Pauline, Pageaux, Georges Philippe, Chiche, Laurence, Deledinghen, Victor, Hardwigsen, Jean, Gugenheim, J., Altieri, M., Hilleret, Marie Noelle, Decaens, Thomas, Duvoux, Christophe, Piñero, Federico, Chagas, Aline, Costa, Paulo, Cristina de Ataide, Elaine, Quiñones, Emilio, Duque, Sergio Hoyos, Marciano, Sebastián, Anders, Margarita, Varón, Adriana, Zerega, Alina, Poniachik, Jaime, Soza, Alejandro, Machaca, Martín Padilla, Arufe, Diego, Menéndez, Josemaría, Zapata, Rodrigo, Vilatoba, Mario, Muñoz, Linda, Menéndez, Ricardo Chong, Maraschio, Martín, Podestá, Luis G., Fauda, M., Campaña, A. Gonzalez, McCormack, Lucas, Mattera, Juan, Gadano, Adrian, Fatima Boin, Ilka S.F., Parente García, Jose Huygens, Carrilho, Flair, Silva, Marcelo, Notarpaolo, Andrea, Magini, Giulia, Miglioresi, Lucia, Gambato, Martina, Di Benedetto, Fabrizio, D’Ambrosio, Cecilia, Ettorre, Giuseppe Maria, Vitale, Alessandro, Burra, Patrizia, Fagiuoli, Stefano, Cillo, Umberto, Colledan, Michele, Pinelli, Domenico, Magistri, Paolo, Vennarecci, Giovanni, Colasanti, Marco, Giannelli, Valerio, Pellicelli, Adriano, Baccaro, Cizia, Degroote, Helena, Van Vlierberghe, Hans, Eduard, Callebout, Samuele, Iesari, Jeroen, Dekervel, Jonas, Schreiber, Jacques, Pirenne, Chris, Verslype, Dirk, Ysebaert, Peter, Michielsen, Valerio, Lucidi, Christophe, Moreno, Olivier, Detry, Jean, Delwaide, Roberto, Troisi, Paul, Lerut Jan, Costentin, Charlotte, Boin, Ilka F., Baccaro, Cinzia, Chagas, Aline Lopes, Di Benedetto, Fabrio, Gadano, Adrián, and Rubinstein, Fernando

Published
2021
Full Text
View/download PDF

3. Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials

Author

Dore, Gregory J., Conway, Brian, Luo, Yan, Janczewska, Ewa, Knysz, Brygida, Liu, Yan, Streinu-Cercel, Adrian, Caruntu, Florin Alexandru, Curescu, Manuela, Skoien, Richard, Ghesquiere, Wayne, Mazur, Włodzimierz, Soza, Alejandro, Fuster, Francisco, Greenbloom, Susan, Motoc, Adriana, Arama, Victoria, Shaw, David, Tornai, Istvan, Sasadeusz, Joseph, Dalgard, Olav, Sullivan, Danielle, Liu, Xuan, Kapoor, Mudra, Campbell, Andrew, and Podsadecki, Thomas

Published
2016
Full Text
View/download PDF

5. FRI-151 - Strategies to eliminate hepatitis C virus infection in the Americas

Author

Diaz, Luis Antonio, García, Sergio, Khan, Rayan, Ayares, Gustavo, Monasterio, Javier Uribe, Idalsoaga, Francisco, Fuentes, Eduardo, Medel, María Paz, Ramirez, Carolina, Lazo, Mariana, Ferreccio, Catterina, Mendizabal, Manuel, Dirchwolf, Melisa, Guerra, Patricia, Oliveira, Claudia, Pessoa, Mário, Álvares-da-Silva, Mario, Sebastiani, Giada, Brahmania, Mayur, Ramji, Alnoor, Niazi, Mina, Ko, Hin HIn, Feld, Jordan J., Restrepo, Juan Carlos, Ramirez, Wagner, Alfaro, Omar, Castellanos-Fernández, Marlen, Carrera, Enrique, Aguirre, Jose Roberto, Maldonado Cardona, Katherine Emilia, Sanchez, Abel, Sánchez, Marco, Andara, Maria Teresa, Castro-Narro, Graciela, Chávez-Tapia, Norberto Carlos, Méndez-Sánchez, Nahum, Adames, Enrique, Lombardo, Julissa, Girala, Marcos, Morán, Elias, Padilla, P. Martin, Diaz-Ferrer, Javier, Tagle, Martin, Mainardi, Victoria, Hernandez, Nélia, Martinez, Edmundo, Alvarado-Tapias, Edilmar, Robert, Leon, Hernandez-Tejero, Maria, De Sicilia, Mauricio Garcia Saenz, Zhang, Wei, Bajaj, Jasmohan S., Tapper, Elliot, Izzy, Manhal, Gish, Robert G., Attar, Bashar, Cotter, Thomas, Kamath, Patrick S., Singal, Ashwani, Bataller, Ramon, Mezzano, Gabriel, Soza, Alejandro, Lazarus, Jeffrey, Arrese, Marco, and Arab, Juan Pablo

Published
2023
Full Text
View/download PDF

7. Hepatitis C virus may have an entero-hepatic cycle which could be blocked with ezetimibe.

Author

Monrroy, Hugo, López-Lastra, Marcelo, and Soza, Alejandro

Subjects
HEPATITIS C treatment, EZETIMIBE, CIRRHOSIS of the liver, MEDICATION safety, TARGETED drug delivery
Abstract

Hepatitis C virus can lead to chronic infection, cirrhosis and hepatocellular carcinoma. With more than 170 million people infected worldwide, eradication remains a challenge even with the revolutionary current direct antiviral agents (DAAs). The risk of resistance, the safety profile in some populations, the genotype specificity and the high price of current DAAs explain why there is still interest in developing host targeting agents (HTA) that may help overcome some of these difficulties. Specifically, targeting the entry of HCV to the cell seems like a promising strategy. Recently it has been shown that the cholesterol transporter NPC1L1, a protein located in the small bowel epithelium and in the canalicular membrane of the hepatocyte is also an HCV receptor. Just as this protein is key in the entero-hepatic cycle of cholesterol, we hypothesize that there is an entero-hepatic cycle of HCV that could be disrupted by blocking NPC1L1 with ezetimibe, an already approved and readily available safe drug. Ezetimibe, either alone or in combination with DAAs, could decrease relapse rates, reduce resistance and even make treatments cheaper. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

8. Disease Progression in Patients With Hepatitis C Virus Infection Treated With Direct-Acting Antiviral Agents.

Author

Mendizabal, Manuel, Piñero, Federico, Ridruejo, Ezequiel, Herz Wolff, Fernando, Anders, Margarita, Reggiardo, Virginia, Ameigeiras, Beatriz, Palazzo, Ana, Alonso, Cristina, Schinoni, María Isabel, Videla Zuain, María Grazia, Tanno, Federico, Figueroa, Sebastián, Santos, Luisa, Peralta, Mirta, Soza, Alejandro, Vistarini, Cecilia, Adrover, Raúl, Fernández, Nora, and Perez, Daniela

Abstract

Little is known about how a sustained virologic response (SVR) to treatment of hepatitis C virus infection with direct-acting antivirals (DAAs) affects patient mortality and development of new liver-related events. We aimed to evaluate the incidence of disease progression in patients treated with DAAs. We performed a prospective multicenter cohort study of 1760 patients who received DAA treatment at 23 hospitals in Latin America, from May 1, 2016, through November 21, 2019. We excluded patients with a history of liver decompensation, hepatocellular carcinoma (HCC), or solid-organ transplantation. Disease progression after initiation of DAA therapy included any of the following new events: liver decompensation, HCC, liver transplantation, or death. Evaluation of variables associated with the primary outcome was conducted using a time-dependent Cox proportional hazards models. During a median follow-up period of 26.2 months (interquartile range, 15.3–37.5 mo), the overall cumulative incidence of disease progression was 4.1% (95% CI, 3.2%–5.1%), and after SVR assessment was 3.6% (95% CI, 2.7%–4.7%). Baseline variables associated with disease progression were advanced liver fibrosis (hazard ratio [HR], 3.4; 95% CI, 1.2–9.6), clinically significant portal hypertension (HR, 2.1; 95% CI, 1.2–3.8), and level of albumin less than 3.5 mg/dL (HR, 4.1; 95% CI, 2.3–7.6), adjusted for SVR achievement as a time covariable. Attaining an SVR reduced the risk of liver decompensation (HR, 0.3; 95% CI, 0.1–0.8; P =.016) and de novo HCC (HR, 0.2; 95% CI, 0.1%–0.8%; P =.02) in the overall cohort. Treatment of hepatitis C virus infection with DAAs significantly reduces the risk of new liver-related complications and should be offered to all patients, regardless of disease stage. Clinicaltrials.gov: NCT03775798. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

9. 1012 MALACHITE-I: Phase 3b Trial of Ombitasvir/Paritaprevir/R and Dasabuvir +/- Ribavirin or Telaprevir + Peginterferon/Ribavirin in Treatment-Naïve Adults With HCV Genotype 1.

Author

Conway, Brian, Janczewska, Ewa, Luo, Yan, Curescu, Manuela, Greenbloom, Susan, Streinu-Cercel, Adrian, Caruntu, Florin A., Ghesquiere, Wayne, Knysz, Brygida, Mazur, Wlodzimierz, Fuster, Francisco, Motoc, Adriana, Soza, Alejandro, Arama, Victoria, Dalgard, Olav, Sullivan, Danielle, Liu, Xuan, and Podsadecki, Thomas

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results